<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nesiritide (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nesiritide (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nesiritide (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="10128" href="/d/html/10128.html" rel="external">see "Nesiritide (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="11225" href="/d/html/11225.html" rel="external">see "Nesiritide (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1027266"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Natriuretic Peptide, B-Type, Human</span>;</li>
<li>
<span class="list-set-name">Vasodilator</span></li></ul></div>
<div class="block don drugH1Div" id="F53462516"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Natrecor is no longer available in the US.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="164f0ba9-5b7e-4481-aa7b-8afb15d10e7b">Decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decompensated heart failure:</b> Very limited data available: <b>Note:</b> Nesiritide is not recommended for first-line therapy; may be considered when other treatment options have failed to lower central venous pressure (CVP) (ISHLT [Kirk 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial bolus (optional): 1 mcg/kg, followed by a continuous infusion of 0.005 to 0.01 mcg/kg/minute; titrate based on clinical response; maximum reported dose: 0.02 mcg/kg/minute. Dosing based on a retrospective review of 17 neonates with decompensated heart failure (PNA: 16 ± 8 days, range: 5 to 31 days; weight: 3.2 ± 0.6 kg, range: 1.8 to 4 kg) who were not responding to conventional therapy; within 24 hours of therapy, nesiritide significantly decreased CVP with a reported treatment duration of 5 ± 4 days. The majority of subjects (12 of 17 neonates) received a bolus dose of 1 mcg/kg with minimal effects on blood pressure and all neonates received a continuous infusion of 0.005 to 0.02 mcg/kg/minute. Most neonates received and responded to 0.01 mcg/kg/minute. Three patients experienced hypotension that required intervention while on therapy; this, however, was not dose related; if hypotension occurs, consider reducing dose or discontinuing infusion; if necessary, other measures to support blood pressure should be initiated. Unlike in other pediatric and adult studies, no difference in urine output was noted (Simsic 2008).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812538"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Natrecor is no longer available in the US.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="164f0ba9-5b7e-4481-aa7b-8afb15d10e7b">Decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decompensated heart failure:</b> Limited data available: <b>Note:</b> Nesiritide is not recommended for first-line therapy; may be considered when other treatment options have failed to lower central venous pressure (CVP) (ISHLT [Kirk 2014]): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial bolus (optional): 1 mcg/kg, followed by continuous infusion of 0.01 mcg/kg/minute; titrate by 0.005 mcg/kg/minute based on clinical response; manufacturer's labeling recommends titrating not more frequently than every 3 hours in adults; usual reported dose range: 0.005 to 0.02 mcg/kg/minute; maximum infusion rate: 0.03 mcg/kg/minute (Jefferies 2007; Mahle 2005). Dosing is based on a retrospective study and an observational study. The retrospective study included 30 pediatric patients (age: median: 4.6 months, range: 5 days to 16.7 years) with heart failure and worsening symptoms despite receiving conventional therapy (eg, inotropic and diuretic therapy). Most patients (80%) received a bolus dose of 1 mcg/kg and all patients received a continuous infusion of 0.005 to 0.02 mcg/kg/minute. Fluid balance and urine output significantly increased after 24 hours of treatment. Minimal effects on blood pressure were reported during infusion; however, one patient required discontinuation due to hypotension (Mahle 2005). Similar results were reported in the observational study of 63 patients (age: 11.97 ± 4.76 years; range: 0.01 to 20.5 years); patients were treated with an initial infusion rate of 0.01 mcg/kg/minute (without bolus dose); if necessary based on clinical response, rate was titrated by 0.005 mcg/kg/minute to a maximum rate of 0.03 mcg/kg/minute. Urine output improved on days 1 and 3 of therapy and only two patients required discontinuation due to hypotension (Jefferies 2007). If hypotension occurs during nesiritide administration, consider reducing dose or discontinuing infusion; if necessary, other measures to support blood pressure should be initiated.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729794"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Use cautiously in patients with renal impairment or those patients who rely on the renin-angiotensin-aldosterone system for renal perfusion. Monitor renal function closely.</p></div>
<div class="block dohp drugH1Div" id="F52729795"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F200831"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10128" href="/d/html/10128.html" rel="external">see "Nesiritide (United States: Not available): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Natrecor is no longer available in the United States.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544fdb8d-9360-4b5b-be1d-3c8dd40a45be">Acute decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure:</b>
<b>IV:</b> Initial: 2 mcg/kg (bolus optional); followed by continuous infusion at 0.01 mcg/kg/minute. <b>Note:</b> Should not be initiated at a dosage higher than initial recommended dose. There is limited experience with increasing the dose &gt;0.01 mcg/kg/minute; in one trial, a limited number of patients received higher doses that were increased no faster than every 3 hours by 0.005 mcg/kg/minute (preceded by a bolus of 1 mcg/kg), up to a maximum of 0.03 mcg/kg/minute. Increases beyond the initial infusion rate should be limited to selected patients and accompanied by close hemodynamic and renal function monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients experiencing hypotension during the infusion:</i> Infusion dose should be reduced or discontinued. Other measures to support blood pressure should be initiated (eg, IV fluids, Trendelenburg position). Hypotension may be prolonged (up to hours); once patient is stabilized, may attempt to restart at a lower dose (reduce previous infusion dose by 30% and omit bolus).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maximum dosing weight:</i> According to the manufacturer, the PRECEDENT Trial capped dosing weight at 160 kg and the VMAC Trial capped dosing weight at 175 kg. There are no specific guidelines on maximum dosing weight and clinical judgment should be used.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990669"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Use cautiously in patients with renal impairment or those patients who rely on the renin-angiotensin-aldosterone system for renal perfusion. Monitor renal function closely.</p></div>
<div class="block doha drugH1Div" id="F50987911"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F200800"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences of adverse reactions include unapproved dosing regimens as well as combination therapy data.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (4% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (28% with &gt;0.5 mg/dL above baseline; 5% with 50% greater serum creatinine levels than at baseline), renal insufficiency (&gt;25% decrease in glomerular filtration rate: 31%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Extravasation, hypersensitivity reactions, pruritus, skin rash</p></div>
<div class="block coi drugH1Div" id="F200813"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to natriuretic peptide or any component of the formulation; cardiogenic shock (when used as primary therapy); hypotension (persistent systolic blood pressure &lt;100 mm Hg) prior to therapy </p></div>
<div class="block war drugH1Div" id="F200798"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Anaphylactic/hypersensitivity reactions: Serious anaphylactic or hypersensitivity reactions may occur following administration; obtain careful history and use caution in patients with previous hypersensitivity to other recombinant peptides; nesiritide prepared through recombinant technology using <i>E. coli</i>.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypotension: May cause hypotension; administer in clinical situations when blood pressure may be closely monitored. Effects may be additive with other agents capable of causing hypotension. Hypotensive effects may last for several hours.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal effects: May be associated with development of azotemia; use caution in patients with renal impairment or in patients where renal perfusion is dependent on renin-angiotensin-aldosterone system (eg, severe heart failure); avoid initiation at doses higher than recommended; increases in serum creatinine may occur at an elevated rate.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Should not be used in patients with low cardiac filling pressures, or in patients with conditions which depend on venous return including significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, and pericardial tamponade.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Prolonged infusions: Use caution with prolonged infusions; limited experience with infusions &gt;96 hours.</p></div>
<div class="block prod-avail drugH1Div" id="F51722962"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Natrecor is no longer available in the US.</p></div>
<div class="block geq drugH1Div" id="F200794"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323489"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Natrecor Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $1,270.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53567925"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">The duration of symptomatic improvement with nesiritide following discontinuation of the infusion has been limited (generally lasting several days). Atrial natriuretic peptide, which is related to nesiritide, has been associated with increased vascular permeability. This has not been observed in clinical trials with nesiritide, but patients should be monitored for this effect.</p></div>
<div class="block admp drugH1Div" id="F52613411"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer as a continuous infusion with the use of an infusion pump. Do not administer through a heparin-coated catheter (concurrent administration of heparin via a separate catheter is acceptable, per manufacturer).</p>
<p style="text-indent:0em;margin-top:2em;">Prime IV tubing prior to connection with vascular access port and prior to administering bolus or starting the infusion. In adults, the bolus is administered over 1 minute; bolus administration rate not reported in pediatric or neonatal trials; slower infusion may be warranted based on hypotension risk; use caution. Begin continuous IV infusion immediately following administration of the bolus.</p></div>
<div class="block adm drugH1Div" id="F200810"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Do not administer through a heparin-coated catheter (concurrent administration of heparin via a separate catheter is acceptable, per manufacturer).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Prime IV tubing with 5 mL of infusion prior to connection with vascular access port and prior to administering bolus or starting the infusion. Withdraw bolus from the prepared infusion bag and administer over 60 seconds. Begin infusion immediately following administration of the bolus.</p></div>
<div class="block sts drugH1Div" id="F200824"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Vials may be stored below 25°C (77°F); do not freeze. Protect from light. Following reconstitution, vials are stable at 2°C to 25°C (36°F to 77°F) for up to 24 hours. Use reconstituted solution within 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53567997"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acutely decompensated congestive heart failure (CHF) in patients with dyspnea at rest or with minimal activity (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F200852"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Natrecor [Canada, Argentina, Venezuela] may be confused with Nitrocor brand name for nitroglycerin [Italy, Russia, Venezuela]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299758"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F200802"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F7913235"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in an animal reproduction study.</p>
<p style="text-indent:0em;margin-top:2em;">Data in humans are inadequate to make recommendations for use in pregnancy (ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53567999"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, hemodynamic responses (PCWP, RAP, CI, CVP), urine output, serum creatinine and blood urine nitrogen</p></div>
<div class="block pha drugH1Div" id="F200797"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to guanylate cyclase receptor on vascular smooth muscle and endothelial cells, increasing intracellular cyclic GMP, resulting in smooth muscle cell relaxation. Has been shown to produce dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure.</p></div>
<div class="block phk drugH1Div" id="F200812"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: PCWP reduction: 15 minutes (60% of 3-hour effect achieved within this time period)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: &gt;60 minutes (up to several hours) for systolic blood pressure; hemodynamic effects persist longer than serum half-life would predict </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>ss</sub>: 0.19 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Proteolytic cleavage by vascular endopeptidases and proteolysis following binding to the membrane bound  natriuretic peptide  (NPR-C) and cellular internalization</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Initial (distribution) ~2 minutes; Terminal: ~18 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily eliminated by metabolism; also excreted in the urine </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539899"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Natrecor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Noratak</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lyophilized recombinant human brain natriuretic peptide | Xin huo su</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Natrecor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Natrecor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Natrecor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Noratak</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12486437">
<a name="12486437"></a>Burger AJ, Horton DP, LeJemtel T, et al, "Effect of Nesiritide (B-Type Natriuretic Peptide) and Dobutamine on Ventricular Arrhythmias in the Treatment of Patients With Acutely Decompensated Congestive Heart Failure: The PRECEDENT Study," <i>Am Heart J</i>, 2002, 144(6):1102-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/12486437/pubmed" id="12486437" target="_blank">12486437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10911006">
<a name="10911006"></a>Colucci WS, Elkayam U, Horton DP, et al, “Intravenous Nesiritide, A Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure. Nesiritide Study Group,” <i>N Engl J Med</i>, 2000, 343(4):246-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/10911006/pubmed" id="10911006" target="_blank">10911006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21164062">
<a name="21164062"></a>Coons JC, McGraw M, and Murali S, "Pharmacotherapy for Acute Heart Failure Syndromes," <i>Am J Health Syst Pharm</i>, 2011, 68(1):21-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/21164062/pubmed" id="21164062" target="_blank">21164062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18154959">
<a name="18154959"></a>Daniels LB and Maisel AS, “Natriuretic Peptides,” <i>J Am Coll Cardiol</i>, 2007, 50(25):2357-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/18154959/pubmed" id="18154959" target="_blank">18154959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17826644">
<a name="17826644"></a>Jefferies JL, Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric heart failure. <i>J Card Fail</i>. 2007;13(7):541-548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/17826644/pubmed" id="17826644" target="_blank">17826644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25110323">
<a name="25110323"></a>Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. <i>J Heart Lung Transplant</i>. 2014;33(9):888-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/25110323/pubmed" id="25110323" target="_blank">25110323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19167692">
<a name="19167692"></a>Kocylowski RD, Dubiel M, Gudmundsson S, et al, “Biochemical Tissue-Specific Injury Markers of the Heart and Brain in Postpartum Cord Blood,” <i>Am J Obstet Gynecol</i>, 2009, 200(3):273.e1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/19167692/pubmed" id="19167692" target="_blank">19167692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16189389">
<a name="16189389"></a>Lev-Sagie A, Bar-Oz B, Salpeter L, “Plasma Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide in Pregnant Women Near Labor and During Early Puerperium,” <i>Clin Chem</i> 2005, 51(10):1909-10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/16189389/pubmed" id="16189389" target="_blank">16189389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16148814">
<a name="16148814"></a>Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. <i>Pediatr Crit Care Med</i>. 2005;6(5):543-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/16148814/pubmed" id="16148814" target="_blank">16148814</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Natrecor (nesiritide) [prescribing information]. Titusville, NJ: Scios LLC; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21732835">
<a name="21732835"></a>O'Connor CM, Starling RC, Hernandez AF, et al, “Effect of Nesiritide in Patients With Acute Decompensated Heart Failure,” <i>N Engl J Med</i>, 2011, 365(1):32-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/21732835/pubmed" id="21732835" target="_blank">21732835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11911755">
<a name="11911755"></a>Publication Committee of the VMAC Investigators (Vasodilation in the Management of Acute CHF), "Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure. A Randomized Controlled Trial," <i>JAMA</i>, 2002, 287(12):1531-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/11911755/pubmed" id="11911755" target="_blank">11911755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15840865">
<a name="15840865"></a>Sackner-Bernstein JD, Kowalski M, Fox M, et al, “Short-Term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials,” <i>JAMA</i>, 2005, 293(15):1900-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/15840865/pubmed" id="15840865" target="_blank">15840865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15781736">
<a name="15781736"></a>Sackner-Bernstein JD, Skopicki HA, and Aaronson KD, “Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure,” <i>Circulation</i>, 2005, 111(12):1487-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/15781736/pubmed" id="15781736" target="_blank">15781736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18805856">
<a name="18805856"></a>Simsic JM, Mahle WT, Cuadrado A, Kirshbom PM, Maher KO. Hemodynamic effects and safety of nesiritide in neonates with heart failure. <i>J Intensive Care Med</i>. 2008;23(6):389-395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nesiritide-united-states-not-available-pediatric-drug-information/abstract-text/18805856/pubmed" id="18805856" target="_blank">18805856</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 116054 Version 71.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
